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1. Deﬁnitions and epidemiology
three types:
-Paroxysmal: recurrent (N1 episode ≥30 s) AFib that terminates
spontaneously within 7 days;
-Persistent: lasts b7 days but necessitates pharmacologic or electro-
cardioversion or is sustained N7 days (deﬁned Longstanding
whenN1 year);
-Permanent: refractory to cardioversion or accepted as a ﬁnal1.1. Chronic obstructive pulmonary disease (COPD)
COPD is a progressive life-threatening obstructive lung disease, char-
acterized by long-term breathing problems and overall poor airﬂow.
The key symptoms include cough with sputum production and short-
ness of breath. With its rising incidence and a prevalence of 251 million
cases globally, COPD represents a major public health problem. The pri-
mary cause of COPD is exposure to tobacco smoke (either active or sec-
ond-hand!); other risk factors include frequent lower respiratory
infections during childhood, indoor and/or outdoor air pollution, and
exposure to occupational dusts, fumes, irritants, and vapors. Notably,
exposure to indoor air pollution can also affect the unborn child and
represents a serious risk factor for developing COPD later in life [1].
Moreover, COPD predisposes to exacerbations and severe illness, in-
cluding cardiac disorders. In fact, the main cause of death in COPD pa-
tients is given by cardiovascular disease rather than respiratory failure.1.2. Atrial ﬁbrillation (AFib)
AFib is a supraventricular arrhythmia characterized by uncoordi-
nated atrial activity. AFib is themost commonly occurring sustained ar-
rhythmia, and its incidence and prevalence is increasing worldwide [2]:
~9% of people ≥65-year-old and ~2% of people b65-year-old have AFib;
AFib is predicted to affect 6–12 million people in the US by 2050 andard.2018.09.056.
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2. COPD and AFib: evidence of an intimate association from clinical
studies
The main parameters to determine the severity of COPD are the
forced expiratory volume in 1 s (FEV1, deﬁned as the maximal volume
of air exhaled in the ﬁrst second of a forced expiration from a position
of full inspiration) and the forced vital capacity (FVC, deﬁned as the
maximal volume of air exhaled with maximally forced effort from a
maximal inspiration).
Interestingly, both FEV1 and FVC have been shown to be inversely
related to the incidence of AFib, in the Copenhagen City Heart Study
[3] and in the Multi-Ethnic Study of Atherosclerosis-Lung Study [4],
respectively. Furthermore, the risk for AFib hospitalization is higher
among patients with low FEV1. A prospective, population-based co-
hort study (Rotterdam Study) demonstrated that COPD is associated
with a 28% increased risk of developing AFib, and that having fre-
quent COPD exacerbations increases the AFib risk approximately 2-
fold [5].
3. Clinical scores and scales useful for risk stratiﬁcation
The following scales are used to quantify the respiratory disability
and provide a prognostic evaluation:
-The Medical Research Council (MRC) dyspnea scale comprises ﬁve
statements that describe almost the entire range of respiratory dis-
ability fromnone (Grade 1) to almost complete incapacity (Grade 5).
-The Dyspnea, Eosinopenia, Consolidation, Acidemia and AFib
(DECAF) score was introduced as a predictor of mortality inlmonary disease linked to atrial ﬁbrillation? A systematic overview of
j.ijcard.2018.10.075
Fig. 1. Potential mechanisms linking COPD and AFib. Several pathogenic mechanisms present in COPD can lead to Aﬁb, including some drugs used to treat COPD. Abbreviations: HIF-1:
Hypoxia-inducible factor 1; LV: left ventricle; MMP: Matrix metalloproteinase; QTc: corrected QT interval; TGF-β1: Transforming growth factor β1; VEGF: Vascular endothelial growth
factor.
2hospitalized patients with COPD exacerbations. The DECAF score in-
cludes in its acronym the 5 strongest predictors of mortality.
-The CURB65 includes the following criteria: Confusion; Blood Urea
N19mg/dL, Respiratory rate ≥ 30 bpm, Blood pressure ≤ 60/90 mm
Hg, Age ≥ 65-years-old.
-The BODE index is a multidimensional 10-point scale which inte-
grates body mass index, degree of airﬂow obstruction and dyspnea,
and exercise capacity. Patientswith higher BODE index scores have a
signiﬁcantly greater prevalence of supraventricular arrhythmias in-
cluding AFib. The score is also directly proportional with mortality.
-The HATCH (Hypertension, Age N 75-year-old, previous Transient
Ischemic Attack or stroke, COPD, Heart failure) score was generated
performing a subgroup analysis studying AFib progression from par-
oxysmal to persistent within the European Heart Survey (EHS); re-
markably, all the HATCH criteria are independent predictors of
AFib progression.
In addition to the above-mentioned scores, a left atrial diameter of
N45 mm and heart failure are among the strongest independent predic-
tors of AFib [6].
4. COPD in AFib patients: a two-way relationship?
Alongside the increased risk of developing AFib observed in COPD
patients, mounting evidence indicates that also the opposite association
occurs. Indeed, the presence of COPD in AFib patients is associated with
AFib progression, recurrence of AFib after catheter ablation, augmented
risk of stroke, and increased cardiovascular mortality. Additionally,
COPD contributes most to the increased all-cause mortality of AFib,
whereas the absence of COPD represents also an independent predictor
for a successful electro-cardioversion at 1-year follow-up [6].Please cite this article as: A. Matarese, et al., Why is chronic obstructive pu
the underlying mechanisms, Int J Cardiol (2018), https://doi.org/10.1016/5. The association of COPD with AFib: the potential underlying
mechanisms
The potential mechanisms underlying the ominous association be-
tween COPD and AFib are depicted in Fig. 1. Hypoxia is deﬁnitely a
key tenet of COPD that can lead to atrial remodeling and eventually to
AFib via an augmented vascular tonewhich elicits pulmonary hyperten-
sion. Several molecular pathways triggered by COPD-related hypoxia
can mediate the pro-ﬁbrotic remodeling of the atrial tissue, including
hypoxia-inducible factor 1 (HIF-1), transforming growth factor β1
(TGF-β1); vascular endothelial growth factor (VEGF), andmatrixmetal-
loproteinases (MMP). Equally important, chronic respiratory acidosis
can prolong atrial depolarization and augment its refractoriness. In-
creased oxidation (includingmitochondrial oxidative stress [7]) and in-
ﬂammation are fundamental features of both COPD and AFib [8], and
have been mechanistically linked to ventricular dysfunction, affecting
diastolic function and causing ECG abnormalities. Supporting this
view, the above-mentioned RotterdamStudy actually indicates that sys-
temic inﬂammation in COPD seems to be crucial in driving the risk of in-
cident AFib [5]. Some of thesemechanisms could also help to enlight the
recently reported relation between obstructive sleep apnea syndrome
(OSAS) and AFib: in fact, OSAS has been shown not only to promote ini-
tiation of AFib but also to have a signiﬁcant negative impact on its
treatment.
Drugs commonly used to treat COPD have been independently asso-
ciated with phenomena that can initiate AFib, including suppression of
the parasympathetic system (anticholinergic drugs), chronotropic ef-
fects (β-adrenergic agonists, especially if not-β2-selective [9]), electro-
lyte depletion, such as increased excretion of potassium and
magnesium (methylxanthines). Moreover, oral glucocorticoids, espe-
cially high-dose steroids, are associated with an increased risk of devel-
oping AFib. Other potential mechanisms not fully studied include
exosomes andmicroRNAs [10], which canmediate a cross-talk between
lungs and atrial cells.lmonary disease linked to atrial ﬁbrillation? A systematic overview of
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